Bengaluru to supply 750m tablets, 75m sachets, 4m bottles to South Africa.
Meiji Seika Pharma Co Ltd says Adcock Ingram Pharma Private Limited has completed construction of a new manufacturing facility in Bengaluru to enhance its production capacity of the contract manufacturing organization (CMO) business.
Commercial production will start from Jan 2024 at the JPY 2.21 billion manufacturing facility has three floors above ground, a total floor area of 7,878 m2, having an annual production capacity of 750 million tablets, 75 million sachets, and 4 million bottles.
This is for Adcock Ingram Pharma Private Limited to manufacture and supply pharmaceutical products not only for the Adcock Ingram Group in South Africa, but also for other clients.
The Meiji Group’s Pharmaceutical Segment, in its 2023 Medium-Term Business Plan, has set an agenda to “Expand CMO/CDMO business” in its business strategies, in which Medreich Limited and Adcock Ingram Limited are regarded as the core companies of the CMO business.
“We will continue to optimize our production bases in Japan and overseas to strengthen our production system and establish the one for stable supply of highly reliable pharmaceuticals and contribute to improving access to pharmaceuticals for people over the world,” the company said in a release on 31 May 2023.
Adcock Ingram Pharma Private Limited, established in 2021, is a wholly-owned subsidiary of Adcock Ingram Limited that is a joint venture between Adcock Ingram Holdings Ltd in South Africa and Medreich Limited.
Adcock Ingram Holdings Ltd. is a leading South African pharmaceutical manufacturer, founded in 1891. Adcock Ingram Holdings Ltd. manufactures, markets and distributes a wide range of healthcare and consumer products, and is a leading supplier to both the private and public sectors of the market. Fiinews.com
